<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Medium Spiny Neurons in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Projection target</td>
<td>GPi, SNr</td>
</tr>
<tr>
<td class="label">Dopamine receptor</td>
<td>D1 family</td>
</tr>
<tr>
<td class="label">Neuropeptide co-release</td>
<td>Substance P</td>
</tr>
<tr>
<td class="label">Effect of dopamine</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Movement facilitation</td>
</tr>
<tr>
<td class="label">Vulnerability in HD</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Clinical correlate</td>
<td>Bradykinesia</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Striatal dopamine</td>
<td>High</td>
</tr>
<tr>
<td class="label">D1 receptor binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">D2 receptor binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dopamine release</td>
<td>Phasic bursts</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tetrabenazine</td>
<td>VMAT inhibitor</td>
</tr>
<tr>
<td class="label">Deutetrabenazine</td>
<td>VMAT inhibitor</td>
</tr>
<tr>
<td class="label">Antipsychotics</td>
<td>D2 antagonists</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Characte
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Medium Spiny Neurons in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Projection target</td>
<td>GPi, SNr</td>
</tr>
<tr>
<td class="label">Dopamine receptor</td>
<td>D1 family</td>
</tr>
<tr>
<td class="label">Neuropeptide co-release</td>
<td>Substance P</td>
</tr>
<tr>
<td class="label">Effect of dopamine</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Movement facilitation</td>
</tr>
<tr>
<td class="label">Vulnerability in HD</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Clinical correlate</td>
<td>Bradykinesia</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Striatal dopamine</td>
<td>High</td>
</tr>
<tr>
<td class="label">D1 receptor binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">D2 receptor binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dopamine release</td>
<td>Phasic bursts</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tetrabenazine</td>
<td>VMAT inhibitor</td>
</tr>
<tr>
<td class="label">Deutetrabenazine</td>
<td>VMAT inhibitor</td>
</tr>
<tr>
<td class="label">Antipsychotics</td>
<td>D2 antagonists</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">R6/2</td>
<td>Rapid progression, juvenile onset</td>
</tr>
<tr>
<td class="label">YAC128</td>
<td>Slow progression, adult onset</td>
</tr>
<tr>
<td class="label">BACHD</td>
<td>Human HTT expression</td>
</tr>
<tr>
<td class="label">HdhQ111</td>
<td>Full-length knock-in</td>
</tr>
</table>
Striatal medium spiny neurons (MSNs) represent the predominant neuronal population within the striatum, constituting approximately 90-95% of all striatal neurons and serving as the primary output projection neurons of the basal ganglia. These GABAergic neurons integrate excitatory inputs from the cerebral cortex and thalamus with modulatory dopaminergic inputs to regulate movement, habit formation, procedural learning, and goal-directed behavior. In Huntington's disease (HD), MSNs undergo progressive and selective degeneration that represents the hallmark neuropathological feature of the disorder, ultimately giving rise to the characteristic motor, cognitive, and psychiatric manifestations that define the clinical phenotype.
The degeneration of MSNs in HD follows a characteristic pattern of vulnerability that has been extensively documented through postmortem neuropathological studies, neuroimaging investigations, and animal model experiments. Understanding the molecular and cellular mechanisms that render MSNs selectively vulnerable to mutant huntingtin (mHTT) toxicity is essential for developing disease-modifying therapeutic interventions that can halt or slow disease progression. This page provides a comprehensive examination of MSN biology, their specific vulnerabilities in HD, the pathogenic mechanisms underlying their degeneration, and current therapeutic strategies aimed at preserving these critical neurons.
Striatal MSNs are classically divided into two major subpopulations based on their projection targets and dopamine receptor expression patterns. The direct pathway MSNs, also known as striatonigral neurons, express the D1 dopamine receptor family (D1A and D1B isoforms) and project directly to the internal segment of the globus pallidus (GPi) and the substantia nigra pars reticulata (SNr). These neurons co-release the neuropeptide substance P and the neurotransmitter GABA, and their activation facilitates movement by disinhibiting thalamocortical circuits [1].
The D1-MSNs form the "go" pathway of the basal ganglia, promoting movement execution when activated by sufficient cortical input in the context of appropriate dopaminergic signaling. In normal physiology, these neurons receive excitatory glutamatergic inputs from motor and premotor cortical areas, dopaminergic inputs from the substantia nigra pars compacta (SNc), and integrate this information to generate appropriate movement output signals.
The indirect pathway MSNs, also known as striatopallidal neurons, express the D2 dopamine receptor family (D2S and D2L isoforms) and project to the external segment of the globus pallidus (GPe). These neurons co-release the neuropeptide enkephalin and GABA, and their activation suppresses movement by inhibiting the GPe, thereby increasing the inhibitory output from GPi to the thalamus [2].
The D2-MSNs form the "no-go" pathway of the basal ganglia, suppressing competing motor programs and allowing for selective movement execution. The balance between direct and indirect pathway activity determines the net output of the basal ganglia and ultimately influences motor behavior.
Medium spiny neurons exhibit distinctive morphological characteristics that enable their identification in histological preparations. The cell bodies of MSNs range from 10-20 μm in diameter and possess dendrites that are densely covered with dendritic spines, which serve as the primary sites of excitatory synaptic input. Each MSN possesses approximately 10,000-15,000 dendritic spines, providing enormous surface area for synaptic contact with corticostriatal and thalamostriatal afferents [4].
The dendritic spine architecture of MSNs is not merely structural but serves crucial functional roles in synaptic plasticity, compartmentalized signaling, and learning. The spine head contains the postsynaptic density (PSD) with glutamate receptors, while the spine neck provides electrical and biochemical isolation that enables calcium signaling to be confined to individual synaptic sites.
The axonal projection pattern of MSNs is highly organized. Each MSN gives rise to a single long axon that exits the striatum and projects to its target nucleus (GPi, GPe, or SNr) with extensive collateral arborization within the striatum itself. These local collaterals form synaptic connections with other MSNs and interneurons, creating the complex intrastriatal circuitry that modulates basal ganglia function [5].
In their resting state, MSNs exhibit a relatively hyperpolarized membrane potential (-70 to -85 mV) due to the high density of inward rectifier potassium (Kir) channels. This resting conductance renders MSNs relatively inexcitable in the absence of sufficient excitatory input, ensuring that spontaneous action potential firing is minimal under baseline conditions.
The input resistance of MSNs ranges from 50-150 MΩ, with the membrane time constant varying between 5-20 ms depending on the MSN subtype and developmental state. These passive membrane properties determine how effectively MSNs integrate synaptic inputs and influence their firing probability.
MSNs integrate diverse synaptic inputs through precisely timed excitatory and inhibitory events. The excitatory glutamatergic inputs from cortex and thalamus drive MSN depolarization, while GABAergic inputs from local interneurons and other MSNs provide inhibition. Dopaminergic inputs modulate both excitatory and inhibitory transmission in a subtype-specific manner [6].
The threshold for action potential generation in MSNs is approximately -40 to -50 mV, and the action potential itself is relatively brief (1-2 ms duration) with characteristic spike height and shape that allows for identification in extracellular recordings.
In vivo, MSN firing exhibits characteristic patterns that correlate with behavior. During movement execution, MSNs fire bursts of action potentials at frequencies of 10-30 Hz, while in the resting state, they exhibit low tonic firing rates (0.1-5 Hz) or complete silence. The transition between these firing states is governed by the balance of synaptic inputs and intrinsic conductances [7].
Postmortem studies of HD brain tissue have consistently demonstrated profound loss of striatal MSNs that correlates with disease severity and clinical phenotype. Quantitative stereological analyses reveal that striatal MSN numbers decrease by 50-80% in advanced HD, with differential vulnerability between subtypes that shifts over the disease course [8].
Early Disease (Premanifest and Early HD)
The pattern of MSN loss within the striatum is not uniform but follows a characteristic anatomical distribution:
The dendritic arbor of MSNs undergoes dramatic restructuring in HD that precedes cell death:
The cell bodies of MSNs also exhibit characteristic pathological changes:
The expanded polyglutamine tract in mutant huntingtin (mHTT) confers toxic gain-of-function properties while simultaneously disrupting normal huntingtin function through loss-of-function mechanisms. The pathogenic effects of mHTT on MSNs are multifaceted and include:
Excessive glutamatergic signaling onto MSNs contributes to their degeneration through several mechanisms:
Multiple defects in mitochondrial function have been documented in HD MSNs:
Activated glial cells surrounding degenerating MSNs release pro-inflammatory cytokines that contribute to neuronal death:
MSN degeneration directly produces the characteristic motor manifestations of HD:
The early predominance of chorea (involuntary, irregular, random movements) correlates with relative preservation of D1-MSNs with more severe loss of D2-MSNs, leading to disinhibition of thalamocortical circuits:
In advanced disease, when both MSN populations are severely affected, parkinsonian features emerge:
The cognitive decline in HD reflects dysfunction of frontostriatal circuits mediated by MSNs:
MSN degeneration in limbic striatum circuits contributes to psychiatric manifestations:
The dopaminergic system exhibits profound alterations secondary to MSN degeneration:
As the primary neurotransmitter of MSNs, GABA output is dramatically reduced:
Corticostriatal glutamate signaling is altered:
Antisense Oligonucleotides (ASOs)